摘要
目的 探讨高血压患者左室肥厚及左室舒张功能与血浆脑钠肽（BNP）浓度的关系.方法 高血压患者62例,其中伴左心室肥厚组患者32例,不伴左心室肥厚组患者30例;健康对照组30名.高血压患者给予厄贝沙坦片75～150 mg/d,治疗6个月.所有对象行超声心动图测定左心室重量指数（LVMI）、E/A（二尖瓣舒张期E峰/A峰）比值.采用美国博适Triage及其试剂盒快速测定血浆BNP水平,对BNP与LVMI、E/A比值作相关分析.结果 高血压左心室肥厚患者组的血浆BNP水平（ng/L）明显高于高血压不伴左心室肥厚患者组和健康对照组（54.8±16.9比36.7±15.4,P＜0.05;54.8±16.9比16.4±12.7,P＜0.05）.经厄贝沙坦治疗后,高血压左心室肥厚患者组血浆BNP水平（ng/L）明显下降（54.8±16.9比36.8±12.6,P＜0.05）,E/A比值明显上升（0.86±0.57比1.09±0.65,P＜0.05）,差异有统计学意义,且与LVMI呈显著正相关 （r＝0.57,P＝0.028）,与E/A比值呈显著负相关（r＝-0.68,P＝0.009）.结论 血浆BNP浓度能较好地反映高血压患者左心室肥厚及左室舒张功能状态.
Objective To study the relationship between brain nat fiuretic peptide （BNP） and left ventricular hypertrophy（LVH） in essential heypertensives （EH）. Methods Echocardiography was performed to determine left ventricular mass index （LVMI） and E/A ratio. Plasma BNP was measured by RIA in 62 cases of hyper- tension with 30 healthy subjects served as control. The hypertensive patients with LVH were treated with Irbesartan Tablets 75-150 mg/d for 6 months. Results Plasma BNP was significantly increased （54.8±16.9 vs 36.7±15.4, P〈0.05, 54.8±16.9 vs 16.4±12.7,P〈0.05） in hypertensive patients with LVH as compared with those without LVH and with health subjects. Irbesartan Tablets treatment significantly decreased plasma BNP and LVMI with LVH （54.8±16.9 vs 36.8±12.6,P〈0.05）, increased E/A ratio in EH with LVH （0.86±0.57 vs 1.09±0.65,P〈 0.05）. The plasma BNP positively was correlate with LVMI（r=0.57,P=0.028） and negatively with E/A ratio（r=- 0.68,P=0.009）. Conclusion Plasma BNP reflects the left vcntricular hypertrophy and cardiodiastolic function in hypertensive patients.
出处
《中国心血管病研究》
CAS
2012年第1期47-49,共3页
Chinese Journal of Cardiovascular Research
关键词
高血压
B型脑钠肽
厄贝沙坦
左室肥厚
左室舒张功能
Essential hypertension
Brain natriuretic peptide
Irbesartan
Left ventricular hypertrophy
Left vcntricular diastolic function
